Franck Mauvais-Jarvis – författare

Hormones—such as estrogens, testosterone, thyroid hormones, and growth hormone—are essential for metabolic homeostasis in all cells. However, their levels decline with age, contributing to aging and chronic disease.  Proper hormone therapy can help delay the onset of age-related diseases, yet there is currently no authoritative, up-to-date resource on precision hormone optimization for healthy aging. Current standard of care textbooks rely on outdated concepts, while books aimed at non-specialist clinicians and patients are often written by non-experts and lack a solid scientific foundation.This book bridges that gap by presenting cutting-edge scientific data and insights from leading academic and private practice experts on the role of hormone optimization in healthy aging. It dispels common misconceptions about hormone therapy risks and highlights the proven benefits of precision hormone treatments. Drawing on both scientific evidence and clinical experience, it explores the distinctions between synthetic hormones and bioidentical, physiological hormones. Designed to challenge conventional thinking, this book aims to inspire discussion and further research among scientists and healthcare practitioners. It is an essential resource for basic and clinical researchers seeking translational knowledge on hormone therapy, as well as clinicians looking to integrate hormone optimization into their practice.

Hormones—such as estrogens, testosterone, thyroid hormones, and growth hormone—are essential for metabolic homeostasis in all cells. However, their levels decline with age, contributing to aging and chronic disease.  Proper hormone therapy can help delay the onset of age-related diseases, yet there is currently no authoritative, up-to-date resource on precision hormone optimization for healthy aging. Current standard of care textbooks rely on outdated concepts, while books aimed at non-specialist clinicians and patients are often written by non-experts and lack a solid scientific foundation.This book bridges that gap by presenting cutting-edge scientific data and insights from leading academic and private practice experts on the role of hormone optimization in healthy aging. It dispels common misconceptions about hormone therapy risks and highlights the proven benefits of precision hormone treatments. Drawing on both scientific evidence and clinical experience, it explores the distinctions between synthetic hormones and bioidentical, physiological hormones. Designed to challenge conventional thinking, this book aims to inspire discussion and further research among scientists and healthcare practitioners. It is an essential resource for basic and clinical researchers seeking translational knowledge on hormone therapy, as well as clinicians looking to integrate hormone optimization into their practice.

The book provides a reference for years to come, written by world-renowned expert investigators studying sex differences, the role of sex hormones, the systems biology of sex, and the genetic contribution of sex chromosomes to metabolic homeostasis and diseases. In this volume, leaders of the pharmaceutical industry present their views on sex-specific drug discovery. Many of the authors presented at the Keystone Symposium on “Sex and gender factors affecting metabolic homeostasis, diabetes and obesity” to be held in March 2017 in Lake Tahoe, CA. This book will generate new knowledge and ideas on the importance of gender biology and medicine from a molecular standpoint to the population level and to provide the methods to study them. It is intended to be a catalyst leading to gender-specific treatments of metabolic diseases.There are fundamental aspects of metabolic homeostasis that are regulated differently in males and females, and influence boththe development of diabetes and obesity and the response to pharmacological intervention. Still, most preclinical researchers avoid studying female rodents due to the added complexity of research plans. The consequence is a generation of data that risks being relevant to only half of the population. This is a timely moment to publish a book on sex differences in diseases as NIH leadership has asked scientists to consider sex as a biological variable in preclinical research, to ensure that women get the same benefit of medical research as men.

The book provides a reference for years to come, written by world-renowned expert investigators studying sex differences, the role of sex hormones, the systems biology of sex, and the genetic contribution of sex chromosomes to metabolic homeostasis and diseases. In this volume, leaders of the pharmaceutical industry present their views on sex-specific drug discovery. Many of the authors presented at the Keystone Symposium on “Sex and gender factors affecting metabolic homeostasis, diabetes and obesity” to be held in March 2017 in Lake Tahoe, CA. This book will generate new knowledge and ideas on the importance of gender biology and medicine from a molecular standpoint to the population level and to provide the methods to study them. It is intended to be a catalyst leading to gender-specific treatments of metabolic diseases.There are fundamental aspects of metabolic homeostasis that are regulated differently in males and females, and influence boththe development of diabetes and obesity and the response to pharmacological intervention. Still, most preclinical researchers avoid studying female rodents due to the added complexity of research plans. The consequence is a generation of data that risks being relevant to only half of the population. This is a timely moment to publish a book on sex differences in diseases as NIH leadership has asked scientists to consider sex as a biological variable in preclinical research, to ensure that women get the same benefit of medical research as men.